Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

Patients with MASLD had nearly twice the all-cause mortality rate as the general population, suggesting the need for multidisciplinary care to reduce excess mortality, researchers said.

Harvard Medical School researchers have found that statin use significantly reduces the risk of hepatocellular carcinoma (HCC) and hepatic decompensation among patients with chronic liver disease (CLD ...

Research published in JAMA Internal Medicine reveals statins may reduce liver cancer risk by 33% and liver complications by ...

One study explored the use of statins, a class of medications typically used to lower LDL cholesterol levels to reduce the ...

Statin users had a significantly lower 10-year cumulative incidence of hepatocellular carcinoma and hepatic decompensation.

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and significantly reduced the risk of HCV-related hepatocellular carcinoma (HCC) ...

Statin use in patients with chronic liver disease was associated with a reduced risk of hepatocellular carcinoma (HCC) and hepatic decompensation, researchers found. In a cohort of 16,501 individuals ...

A comprehensive study shows that people with fatty liver disease have almost twice the mortality rate of the general population. They have an increased risk of dying from both liver diseases and ...

Researchers found that statin use decreased the risk for hepatocellular carcinoma and hepatic decompensation, which is an advanced stage of liver disease. The authors found that statin use appeare ...

The analysis included 16,501 participants: 3610 statin users and 12,891 nonusers. HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for ...